MedTrace Logo

Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects

NCT00979316 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2011-01-07

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).

Conditions

  • Alzheimer Disease

Interventions

DRUG

BMS-708163

Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days

DRUG

BMS-708163

Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days

DRUG

Placebo

Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days

DRUG

Moxifloxacin

Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979316 on ClinicalTrials.gov